Barinthus Biotherapeutics plc
BRNS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5 | $7 | $8 | $6 |
| G&A Expenses | $5 | $15 | $13 | $3 |
| SG&A Expenses | $5 | $15 | $13 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $1 | -$0 | $14 |
| Operating Expenses | $15 | $23 | $21 | $23 |
| Operating Income | -$15 | -$23 | -$21 | -$23 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $2 | $1 | $3 |
| Pre-Tax Income | -$15 | -$21 | -$20 | -$21 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | -$15 | -$21 | -$20 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.52 | -0.49 | -0.51 |
| % Growth | 30.8% | -6.1% | 3.9% | – |
| EPS Diluted | -0.36 | -0.52 | -0.49 | -0.51 |
| Weighted Avg Shares Out | 41 | 40 | 40 | 39 |
| Weighted Avg Shares Out Dil | 41 | 40 | 40 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $2 | $2 | $1 |
| EBITDA | -$13 | -$19 | -$18 | -$19 |
| % Margin | – | – | – | – |